PATENT CLAIM ANALYSIS

Application Number: 16265546
Application Type: Utility
Filing Date: 2019-02
Publication Date: 2019-05
Patent Classification: ["800", "008000"]

Abstract:
A method of radiation-free hematopoietic stem cell (HSC) transplantation comprises administering to a mammalian subject one or two doses of 2 to 10 mg/kg body weight of a purine base analog, such as 6TG as a pre-conditioning step. The method further comprises engrafting into the subject hypoxanthine-guanine phosphoribosyltransferase (HPRT)-deficient donor HSCs within 48 to 72 hours of the pre-conditioning step; and administering to the subject about 1 to 5 mg/kg of the purine base analog every two to four days for two to eight weeks following the engrafting step. The method is performed in the absence of pre-conditioning via radiation. The subject is therefore not treated with myeloablative radiation in preparation for transplantation, and thus the subject is free of myeloablative radiation-induced toxicity.

Claim (Index 13):
The method of  claim 1 , wherein the total 6TG dosage administered to the subject in the administering of step (b) does not exceed 105 mg.

Metadata:
- Claim Count in Document: 119.0
- Percentile: 99.0
- Lexical Diversity: 1.70886
- Patent Class: 800.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15625819', '15155776', '14112878', '16038643', '14359756']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.723903552829149
- 35 USC 102 Novelty (BERT): 0.7657824806296382
- Combined Prediction Score: 0.7280914456091978
- Mean Citation Score: 672.2076840000002
- Max Citation Score: 920.14825
- Similarity Product: 916.705512781322

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 0

Dataset: test